What is the difference between CJC-1295 / Ipamorelin Stack and Ipamorelin?

CJC-1295 / Ipamorelin Stack: The CJC-1295 (without DAC) and Ipamorelin combination is the most widely researched and community-validated growth hormone secretagogue stack. By pairing a GHRH analog with a selective GHRP, the two peptides act synergistically — producing GH pulses significantly larger than either compound alone, while maintaining a physiological pulse pattern and minimal side effects. Ipamorelin: Ipamorelin is a selective growth hormone secretagogue (GHS) and ghrelin receptor agonist. It stimulates GH release with high selectivity — minimal cortisol or prolactin elevation compared to older GHRPs. Widely used in research protocols for body composition, sleep quality, and recovery. Both are in the Performance & Growth Hormone category but differ in mechanism, dosing, and research evidence — see the full comparison.

Can you take CJC-1295 / Ipamorelin Stack and Ipamorelin together?

There is no specific, well-documented interaction rule for combining CJC-1295 / Ipamorelin Stack and Ipamorelin in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, CJC-1295 / Ipamorelin Stack or Ipamorelin?

CJC-1295 / Ipamorelin Stack is currently fda-approved and Ipamorelin is investigational (in trials). "Better researched" depends on your research goal — review each profile's cited sources.

Performance & Growth Hormone · Comparison

CJC-1295 / Ipamorelin Stack vs Ipamorelin

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

CJC-1295 / Ipamorelin Stack

FDA-approved

The CJC-1295 (without DAC) and Ipamorelin combination is the most widely researched and community-validated growth hormone secretagogue stack. By pairing a GHRH analog with a selective GHRP, the two peptides act synergistically — producing GH pulses significantly larger than either compound alone, while maintaining a physiological pulse pattern and minimal side effects.

Full profile

Ipamorelin

Investigational (in trials)

Ipamorelin is a selective growth hormone secretagogue (GHS) and ghrelin receptor agonist. It stimulates GH release with high selectivity — minimal cortisol or prolactin elevation compared to older GHRPs. Widely used in research protocols for body composition, sleep quality, and recovery.

Full profile

	CJC-1295 / Ipamorelin Stack	Ipamorelin
Category	Performance & Growth Hormone	Performance & Growth Hormone
Also known as	CJC-1295 Ipamorelin, Mod GRF 1-29 Ipamorelin, CJC Ipa stack, CJC-1295 without DAC with Ipamorelin, GHRH GHRP combination	NNC 26-0161, Ipamorelin acetate
Evidence	FDA-approved	Investigational (in trials)
Dosing range	100mcg each–300mcg each mcg, once daily before sleep (or 2–3x daily for more aggressive protocols)	100mcg–300mcg mcg, 1–3x daily (typically pre-sleep and/or pre-workout)
Administration	Subcutaneous injection (both compounds), Administered together in the same injection	Subcutaneous injection, Intramuscular injection
Key side effects	Water retention (mild, common), Tingling or numbness in hands/feet (transient), Headache (usually first 1–2 weeks), Fatigue or increased sleepiness (often desired at night dose)	Water retention (mild), Tingling / numbness in extremities, Increased appetite, Headache (transient)
Cited sources	2 references	3 references

Key differences

Evidence level differs: CJC-1295 / Ipamorelin Stack is fda-approved, while Ipamorelin is investigational (in trials).
Administration: CJC-1295 / Ipamorelin Stack — Subcutaneous injection (both compounds), Administered together in the same injection; Ipamorelin — Subcutaneous injection, Intramuscular injection.
Frequency: CJC-1295 / Ipamorelin Stack is typically once daily before sleep (or 2–3x daily for more aggressive protocols); Ipamorelin is 1–3x daily (typically pre-sleep and/or pre-workout).
Research depth: this profile cites 2 sources for CJC-1295 / Ipamorelin Stack vs 3 for Ipamorelin.

How each works

CJC-1295 / Ipamorelin Stack

CJC-1295 without DAC (Mod GRF 1-29) stimulates GHRH receptors on the pituitary, increasing the amplitude of GH pulses. Ipamorelin independently triggers GH release via the ghrelin receptor (GHS-R1a) with high selectivity — minimal cortisol, prolactin, or aldosterone co-elevation. The combination exploits two separate receptor pathways to produce synergistic GH output. Animal and human studies on each compound individually confirm GH and IGF-1 elevation. The combination is extrapolated from mechanistic research and is the most studied protocol in the peptide research community.

Ipamorelin

Ipamorelin selectively stimulates GH release via the ghrelin receptor (GHS-R1a) without significantly elevating ACTH or cortisol — the feature that distinguishes it from GHRP-6 and GHRP-2 (Raun et al., 1998, in swine/rodent models). Human data are limited: a PK study in 40 volunteers established a ~2-hour half-life (Gobburu et al., 1999), and a Phase 2 trial for postoperative ileus (Beck et al., 2014) failed its primary endpoint. It is not FDA-approved, and claims about body composition or recovery are extrapolated from GH physiology, not human outcome trials.

Read the full CJC-1295 / Ipamorelin Stack profile Read the full Ipamorelin profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.